Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1%
- 20 December 2007
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 22 (1), 113-115
- https://doi.org/10.1111/j.1468-3083.2007.02280.x
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Treatment recommendations for pyoderma gangrenosum: An evidence-based review of the literature based on more than 350 patientsJournal of the American Academy of Dermatology, 2005
- Topical Tacrolimus Therapy for Pyoderma GangrenosumThe Journal of Dermatology, 2005
- Corticosteroids But Not Pimecrolimus Affect Viability, Maturation and Immune Function of Murine Epidermal Langerhans CellsJournal of Investigative Dermatology, 2004
- Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimusInternational Journal of Pharmaceutics, 2003
- The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophilsJournal of Allergy and Clinical Immunology, 2001
- Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expressionBritish Journal of Dermatology, 1995
- Pyoderma gangrenosum. Abnormal monocyte function corrected in vitro with hydrocortisoneArchives of Dermatology, 1978
- Pyoderma gangrenosum, altered delayed hypersensitivity and polyarthritisArchives of Dermatology, 1972
- Pyoderma Gangrenosum, Altered Delayed Hypersensitivity, and PolyarthritisArchives of Dermatology, 1972